Endogen HP Indications/Uses

Ovulation Induction: Urofollitropin (Endogen HP) administered SC or IM in conjunction with hCG, (Pubergen JO 7500 IU) is indicated for ovulation induction in patients who have previously received pituitary suppression.
Multifollicular Development during ART: Urofollitropin (Endogen HP) administered SC in conjunction with hCG is indicated to multiple follicular development (controlled ovarian stimulation) during ART cycles inpatients who have previously received pituitary suppression.
Selection of Patients: 1. Before treatment with Urofollitropin (Endogen HP) is instituted, a thorough gynecologic and endocrine evaluation must be performed. Except for those patients enrolled in an in vitro fertilization program, this should include a hysterosalp in angiography (to rule out uterine and tubal pathology) and documentation of anovulation by means of basal body temperature, serial vaginal smears, examination. of cervical mucus, determination of serum (or urine) progesterone, urinary pregnanediol and endometrial biopsy.
2. Primary ovarian failure should be excluded by the determination of gonadotropin levels.
3. Careful examination should be made to rule out the presence of an early pregnancy.
4. Patients in late reproductive life have a greater predilection to endometrial carcinoma as well as higher incidence of anovulatory disorders, Cervical dilation and curettage should always be done for diagnosis before starting Urofollitropin (Endogen HP) therapy in such patients who demonstrate abnormal uterine bleeding or other signs of endometrial abnomalities.
5. Evaluation of the husband's fertility potential should be included in the workup.